Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Dumping Syndrome Treatment & Management

  • Author: Rajan Kanth, MD; Chief Editor: BS Anand, MD  more...
 
Updated: Mar 03, 2016
 

Medical Care

Acarbose

The use of acarbose, an alpha-glycoside hydrolase inhibitor, interferes with carbohydrate absorption and thus may decrease the time delay between hyperglycemia and insulin response. This may lead to coinciding the peak of glucose and insulin levels and thus prevent hypoglycemic symptoms in patients with late dumping. Imhof et al showed that acarbose produced a 5-fold decrease in postprandial glucagon-like peptide 1 levels which, in turn, may lead to a decrease in insulin release.[26]

Acarbose use may be limited by the occurrence of diarrhea secondary to fermentation of unabsorbed carbohydrates as manifested by increased breath hydrogen excretion and symptoms such as flatulence.

Acarbose delays production of monosaccharides by inhibiting alpha-glucosidases associated with the brush border of the intestine. These enzymes are responsible for the digestion of complex polysaccharides and sucrose.

In healthy individuals, acarbose in doses of 100-200 mg significantly blunts the postprandial rise in glucose, insulin, and triglycerides. Acarbose has been shown to significantly lower postprandial blood glucose levels.

Octreotide

Somatostatin and its synthetic analogue octreotide (Sandostatin, SMS 201-995) have been used with short-term success in patients with dumping syndrome, but the long-term efficacy of octreotide is much less favorable. They exert a strong inhibitory effect on the release of insulin and several gut-derived hormones.

In patients with dumping syndrome, octreotide likely decreases gastric emptying by resetting the migrating motor complex to the fasting level.

The effectiveness of octreotide in controlling the symptoms of both early and late dumping has been demonstrated in several randomized control trials.

The mechanisms of action of octreotide in dumping syndrome are as follows:

  • Delay in the accelerated initial gastric emptying
  • Delay in small intestinal transit time
  • Inhibition of enteral hormone release
  • Induction of a fasting intestinal pattern
  • Inhibition of insulin release
  • Splanchnic vasoconstriction
  • Inhibition of postprandial vasodilation

The usual initial dose of octreotide is 50 mcg administered subcutaneously bid/tid 30 minutes prior to each meal. The dose may be increased if smaller doses are not effective; however, higher doses are seldom effective if the smaller doses do not work.

Octreotide improves the symptoms in about 90% of patients with severe dumping refractory to other forms of medical interventions.

In all studies, octreotide in the short term decreased the symptom score, pulse rate, and plasma insulin levels when compared with placebo. However, whether long-term octreotide use is as beneficial as short-term use is unclear. Reports on long-term use of octreotide are scarce, and the number of patients in these reports is small.

During octreotide treatment, fecal fat excretion increases significantly. Despite this increase in steatorrhea, an increase in mean body weight is reported. This probably occurs because of increased energy intake as patients are able to tolerate more food.

Octreotide appears to be safe in the long-term management of refractory dumping syndrome; however, the occurrence of diarrhea in patients who already have malabsorption and maldigestion may be a major limiting factor.

Depot long-acting release octreotide (Sandostatin-LAR), as compared with octreotide, resulted in a significantly greater GI-specific quality-of-life index and body weight gain.[24, 27] However, the effect of octreotide on late dumping symptoms was superior to the effect of long-acting octreotide.[28]

Although the results of long-term use of octreotide injections are less dramatic than short-term use, nonetheless, symptoms are reduced by about 50%.[29] Other authors report that long-acting release octreotide is as effective long term as subcutaneous octreotide, with superior symptom control as assessed by the Gastrointestinal Specific Quality of Life Index, better maintenance of body weight, and higher quality of life.[24]

The addition of verapamil may also be considered.[30] Although there is enthusiasm for the use of electrical stimulation of the small intestine to achieve gastrointestinal pacing as a treatment of dumping syndrome,[31] there are no placebo-controlled trials, thus, possible placebo effects cannot be excluded.

Next

Surgical Care

Preventing dumping syndrome is preferable to treating its symptoms. Consider anatomic factors that relate to the syndrome, and, if possible, determine the exact type of surgical procedure needed. Numerous alimentary reconstruction methods have been proposed to treat the dumping syndrome.[32] Proximal gastric vagotomy is now the procedure of choice for the surgical management of intractable ulcer disease. Although the long-term ulcer recurrence rate is higher after this procedure compared with antrectomy and truncal vagotomy, it has the lowest incidence of postoperative dumping and diarrhea. If more extensive surgery is necessary, resection is preferable to a Roux-en-Y gastrojejunostomy, because it decreases the rate of dumping syndrome compared with pyloroplasty or loop gastrojejunostomy.

Remedial surgery can be considered in patients whose condition is refractory to medical treatment or in patients unwilling to continue medical therapy. Patients should be approached conservatively, because most patients improve with time and remedial surgery is not always effective.

Several surgical procedures have been designed to rectify the symptoms of dumping. These include surgical narrowing of the gastrojejunal stoma, conversion of Billroth II anastomosis to Billroth I gastroduodenostomy, jejunal interposition, conversion to Roux-en-Y gastrojejunostomy, and pyloric reconstruction. No long-term studies have assessed the effectiveness of these procedures. Furthermore, no controlled trials have examined the efficacy of one procedure compared to the other.

For early gastric cancer, the postoperative outcome is better in those having a pylorus-preserving gastrectomy.[33] Unfortunately, about one quarter of patients undergoing a pylorus-preserving gastrectomy may have sufficiently symptomatic delayed gastric emptying that the quality of their life may be adversely affected.[34]

Stomal revision

One strategy for surgical correction of the pathophysiology of dumping is to slow gastric emptying.

Porter and Claman reported good results by narrowing the gastrojejunal stoma.[35]

Determining the exact size of the stomal reconstruction is difficult.

Stomal strictures with gastric outlet obstruction are common adverse effects of the operation.

This technique has been abandoned in favor of other procedures.

Conversion of Billroth II to Billroth I anastomoses

Conversion of a Billroth II to a Billroth I gastroduodenostomy improves dumping syndrome in 75% of patients.[36]

This procedure restores the physiologic delivery of the meal to the duodenum, without risk of gastric outlet obstruction.

Overall, the procedure is useful because of its simplicity and low rate of complications.

Pyloric reconstruction

In this procedure, the pyloroplasty scar is identified and is cut along its length. The sphincter muscle is identified and approximated. The incision is then closed longitudinally.

In a series of 14 patients reported by Koruth et al, 9 showed excellent results, whereas another 3 had good resolution of their dumping symptoms.[37]

Cheadle and coworkers reported a series of 9 patients, 8 of whom had excellent results.[38]

This procedure is low-risk and seems to be fairly effective in patients who have severe dumping after pyloroplasty.

Jejunal interposition

Schoemaker is credited with the first attempt at interposing an isoperistaltic jejunal loop after gastric surgery.

Henley has reported extensive use of an interposed jejunal segment between the gastric pouch and the duodenum for correction of postgastrectomy dumping in more than 300 patients.[39] In his series, all patients improved, including those with early postprandial dumping. However, other smaller series have failed to show such excellent results with the use of isoperistaltic interposition.

Sawyers and Herrington had only a 20% satisfactory result in 10 patients.[40] In an 11-year experience using antiperistaltic jejunal loops in 28 patients, they reported excellent results in 20 patients and good results in another 6 patients. In their experience, a 10-cm reversed jejunal segment effectively prolongs the gastric emptying time without obstruction.

Unsuccessful results with interposition of 6 cm of reversed jejunal segments have been reported, whereas good results have been reported with 10-cm segments.

Using longer lengths of jejunum has resulted in ulcerations and stenosis in the interposed segment. Care should be taken to rotate the interposed segment no greater than 180° to avoid undue torsion on the mesentery. Mesenteric defects should be carefully repaired to avoid internal herniation.

Reversed segments have been shown to be effective for as long as 10 years after interposition.

Double iso-antiperistaltic jejunal limb pouches have also been used, but their efficacy is inferior to the antiperistaltic loop interposition.

Roux-en-Y conversion

Conversion to a Roux-en-Y gastrojejunostomy as a remedial operation has gained favor relatively recently. With this operation, favorable outcomes have been reported in 85-90% of patients. Of patients with dumping symptoms after Billroth I and II gastrectomy, 85-90% have favorable outcomes with Roux-en-Y conversion.

Vogel et al reported 19 of 22 patients with favorable outcomes with this operation.[41] Of the 3 failures, 1 had persistent dumping syndrome, whereas the other 2 patients had Roux stasis syndrome.

The mechanism by which this conversion works in providing relief from dumping is unknown, but it may be due to interruption of the migration motor complex, diminished jejunal contractions, and retrograde jejunal contractions.

This procedure is easier to perform and has fewer long-term adverse effects.

Bariatric surgery[42]

Hyperinsulinemic hypoglycemia with neuroglycopenia is an increasingly recognized complication of Roux-en-Y gastric bypass due to the changes in gut hormonal milieu.[43] Management includes strict low carbohydrate diet, followed by pharmacotherapy.

The dumping syndrome that occurs after gastric bypass surgery is not due to an increase in pancreatic beta cell formation or mass; instead, it is due to hypersensitivity of the postprandial insulin response.[44] This inappropriately increased insulin secretion may be due to excessively high incretin levels, or to "…a failure to adequately decrease insulin secretion…."[44]

Within 30 minutes after a high-carbohydrate meal, 12 of 14 patients were shown-to develop hyperglycemia and hyperinsulinemia (noninsulinoma, pancreatogenous hypoglycemic syndrome [NIPHS]) some 30 minutes after a test meal, whereas this and the associated symptoms did not occur with a low-carbohydrate diet.[45]

Dietary considerations are important after bariatric surgery, and the patient’s diet may need to be specifically formulated to deal with symptoms such as dumping, altered bowel habit, nausea and vomiting, dehydration, food intolerance, and overeating.[46]

Diffuse islet cell hyperplasia and expansion of the beta cell mass have been described in 3 patients with severe postprandial hyperglycemia and hyperinsulinemia unresponsive to diet, octreotide, and diazoxide.

Laparoscopic conversion

Laparoscopic conversion of laparoscopic Roux-en-Y gastric bypass to laparoscopic sleeve gastrectomy, biliopancreatic diversion with duodenal switch, or original anatomy has been tried recently as a feasible and safe option for cases refractory to medical treatment.[47, 48, 49] However, 33-40% of patients after laparoscopic sleeve gastrectomy may still have symptoms of dumping syndrome 6-12 months after surgery. In these cases, symptoms include both early and late dumping symptoms, but there is progressive increase in late symptoms.[50]

Experimental procedures

Because no operation for intractable dumping is uniformly successful, new approaches have been considered

In dogs prepared with truncal vagotomy, distal gastrectomy, and Roux-en-Y reconstruction, retrograde electrical pacing of the Roux-en-Y reconstruction significantly delayed gastric emptying and absorption of a glucose meal and decreased postcibal hemoconcentration.

Summary of remedial operations

For patients with prior pyloroplasty, pyloric reconstruction should be the initial remedial operation.

For patients with Billroth I and Billroth II gastrectomies, Roux-en-Y reconstruction is the simplest and most effective therapy.

For patients who already have a Roux-en-Y reconstruction, a 10-cm antiperistaltic jejunal loop should be interposed.

Conclusion

Dumping syndrome is a common postsurgical complication after gastric surgery. The symptoms of dumping produce considerable morbidity. Fortunately, the indications for gastric surgery are declining, although the need for gastric surgery in emergency cases has not changed.

Initially, patients with this condition should be treated medically with dietary modifications and octreotide. Close attention should be given to the patient's nutritional status. If medical management fails to provide adequate symptom relief, remedial surgery should be offered with the understanding that even surgical intervention may not be successful.

Previous
Next

Diet

Dietary prohibitions and instructions are very important in the management of dumping syndrome. Note the following:

  • Daily energy intake is divided into 6 meals.
  • Fluid intake during and with meals is restricted. Avoiding liquids for at least half an hour after a meal is helpful.
  • Simple sugars are best avoided.
  • Milk and milk products are generally not tolerated and should be avoided.
  • Because carbohydrate intake is restricted, protein and fat intake should be increased to fulfill energy needs.
  • Most patients have relatively mild symptoms and respond well to dietary manipulations. In some patients with postprandial hypotension, lying supine for 30 minutes after meals may delay gastric emptying and also increase venous return, thereby minimizing the chances of syncope.
  • Supplementation with dietary fiber has proven effective in the treatment of hypoglycemic episodes. Many medical therapies have been tested, including pectin, guar gum, and glucomannan. These dietary fibers form gels with carbohydrates, resulting in delayed glucose absorption and prolongation of bowel transit time.
  • This dietary change to a low-carbohydrate, high protein diet, as well as the use of alpha-glucosidase inhibitors, may be useful to control the symptoms of dumping. [51, 52] This is preferential to subtotal or total pancreatectomy in those persons with severe symptoms.
Previous
 
 
Contributor Information and Disclosures
Author

Rajan Kanth, MD Hospitalist, Ministry Saint Joseph’s Hospital

Rajan Kanth, MD is a member of the following medical societies: American College of Physicians, Society of Hospital Medicine, Nepal Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Praveen K Roy, MD, AGAF Chief of Gastroenterology, Presbyterian Hospital; Medical Director of Endoscopy, Presbyterian Medical Group; Adjunct Associate Research Scientist, Lovelace Respiratory Research Institute

Praveen K Roy, MD, AGAF is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Additional Contributors

Vivek V Gumaste, MD Associate Professor of Medicine, Mount Sinai School of Medicine of New York University; Adjunct Clinical Assistant, Mount Sinai Hospital; Director, Division of Gastroenterology, City Hospital Center at Elmhurst; Program Director of GI Fellowship (Independent Program); Regional Director of Gastroenterology, Queens Health Network

Vivek V Gumaste, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association

Disclosure: Nothing to disclose.

Acknowledgements

Thomas Aguirre, MD Gastroenterology Fellow, Department of Internal Medicine, University of Arizona

Thomas Aguirre, MD is a member of the following medical societies: American College of Gastroenterology and American College of Physicians

Disclosure: Nothing to disclose.

Sukhdeep Padda, MBBS Staff Physician, Arrowhead Gastroenterology

Sukhdeep Padda is a member of the following medical societies: American College of Gastroenterology

Disclosure: Nothing to disclose.

Francisco Ramirez, MD, FACG Consultant, Gastroenterology Director, Esophageal Clinic Quality; Professor of Medicine, Mayo School of Medicine

Francisco Ramirez, MD is a member of the following medical societies: American College of Gastroenterology

Disclosure: Nothing to disclose.

Alan BR Thomson, MD Professor of Medicine, Division of Gastroenterology, University of Alberta, Canada

Alan BR Thomson, MD is a member of the following medical societies: Alberta Medical Association, American College of Gastroenterology, American Gastroenterological Association, Canadian Association of Gastroenterology, Canadian Medical Association, College of Physicians and Surgeons of Alberta, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

References
  1. Borrelli D, Borrelli A, Presenti L, Bergamini C, Basili G. [Surgical approach of the functional post-partial gastrectomy syndromes] [Italian]. Ann Ital Chir. 2007 Jan-Feb. 78(1):3-10. [Medline].

  2. Hertz AF. IV. The Cause and Treatment of Certain Unfavorable After-effects of Gastro-enterostomy. Ann Surg. 1913 Oct. 58(4):466-72. [Medline].

  3. Wyllys E, Andrews E, Mix CL. "Dumping stomach" and other results of gastrojejunostomy: Operative cure by disconnecting old stoma. Surg Clin Chicago. 1920. 4:879-92.

  4. Ukleja A. Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract. 2005 Oct. 20(5):517-25. [Medline].

  5. Berg P, McCallum R. Dumping syndrome: a review of the current concepts of pathophysiology, diagnosis, and treatment. Dig Dis Sci. 2016 Jan. 61 (1):11-8. [Medline].

  6. Azpiroz F, Malagelada JR. Gastric tone measured by an electronic barostat in health and postsurgical gastroparesis. Gastroenterology. 1987 Apr. 92(4):934-43. [Medline].

  7. Ishikawa K, Arita T, Ninomiya S, et al. Outcome of segmental gastrectomy versus distal gastrectomy for early gastric cancer. World J Surg. 2007 Nov. 31(11):2204-7. [Medline].

  8. Braghetto I, Papapietro K, Csendes A, et al. Nonesophageal side-effects after antireflux surgery plus acid-suppression duodenal diversion surgery in patients with long-segment Barrett's esophagus*. Dis Esophagus. 2005. 18(3):140-5. [Medline].

  9. Rivera I, Ochoa-Martinez CI, Hermosillo-Sandoval JM, et al [Spanish]. [Dumping syndrome in patients submitted to gastric resection]. Cir Cir. 2007 Nov-Dec. 75(6):429-34. [Medline].

  10. Thalhammer M, Cuk A, Palitzsch KD. [Postalimentary hypoglycaemia in post-gastrectomy late dumping syndrome] [German]. Dtsch Med Wochenschr. 2005 Feb 25. 130(8):393-6. [Medline].

  11. Spiller R. Role of motility in chronic diarrhoea. Neurogastroenterol Motil. 2006 Dec. 18(12):1045-55. [Medline].

  12. Morioka J, Miyachi M, Niwa M, et al. Gastric emptying for liquids and solids after distal gastrectomy with Billroth-I reconstruction. Hepatogastroenterology. 2008 May-Jun. 55(84):1136-9. [Medline].

  13. Kalser MH, Cohen R. Correlation of jejunal transfer of water and electrolytes with blood volume in postgastrectomy patients: response to hypertonic glucose meal. Ann Surg. 1966 Nov. 164(5):821-9. [Medline].

  14. Hinshaw DB, Joergerson EJ, Davis HA. Peripheral blood flow and blood volume studies in the dumping syndrome. Arch Surg. 1957. 74:686.

  15. Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab. 2007 Dec. 92(12):4678-85. [Medline].

  16. Yamamoto H, Mori T, Tsuchihashi H, et al. A possible role of GLP-1 in the pathophysiology of early dumping syndrome. Dig Dis Sci. 2005 Dec. 50(12):2263-7. [Medline].

  17. Akimov VP, Dvaladze LG, Shengelia TD, Veselov IuE. [A new view on pathogenesis of dumping-syndrome] [Russian]. Vestn Khir Im I I Grek. 2008. 167(6):22-5. [Medline].

  18. Deitel M. The change in the dumping syndrome concept. Obes Surg. 2008 Dec. 18(12):1622-4. [Medline].

  19. Holdsworth CD, Turner D, McIntyre N. Pathophysiology of post-gastrectomy hypoglycaemia. Br Med J. 1969 Nov 1. 4(5678):257-9. [Medline].

  20. Seyfried F, Wierlemann A, Bala M, Fassnacht M, Jurowich C. [Dumping syndrome: diagnostics and therapeutic options] [German]. Chirurg. 2015 Sep. 86 (9):847-54. [Medline].

  21. Mala T, Hewitt S, Hogestol IK, Kjellevold K, Kristinsson JA, Risstad H. [Dumping syndrome following gastric surgery] [Norwegian]. Tidsskr Nor Laegeforen. 2015 Jan 27. 135 (2):137-41. [Medline].

  22. Z'graggen K, Guweidhi A, Steffen R, et al. Severe recurrent hypoglycemia after gastric bypass surgery. Obes Surg. 2008 Aug. 18(8):981-8. [Medline].

  23. Schneider A, Gottrand F, Sfeir R, Duhamel A, Bonnevalle M, Guimber D, et al. Postoperative Lower Esophageal Dilation in Children Following the Performance of Nissen Fundoplication. Eur J Pediatr Surg. 2012 Jul 7. [Medline].

  24. Virji A, Murr MM. Caring for patients after bariatric surgery. Am Fam Physician. 2006 Apr 15. 73(8):1403-8. [Medline].

  25. Laurenius A, Olbers T, Näslund I, Karlsson J. Dumping Syndrome Following Gastric Bypass: Validation of the Dumping Symptom Rating Scale. Obes Surg. 2013 Jan 14. [Medline].

  26. Imhof A, Schneemann M, Schaffner A, Brändle M. Reactive hypoglycaemia due to late dumping syndrome: successful treatment with acarbose. Swiss Med Wkly. 2001 Feb 10. 131(5-6):81-3. [Medline].

  27. Penning C, Vecht J, Masclee AA. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome. Aliment Pharmacol Ther. 2005 Nov 15. 22(10):963-9. [Medline].

  28. Arts J, Caenepeel P, Bisschops R, et al. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping. Clin Gastroenterol Hepatol. 2009 Apr. 7(4):432-7. [Medline].

  29. De Cunto A, Barbi E, Minen F, Ventura A. Safety and efficacy of high-dose acarbose treatment for dumping syndrome. J Pediatr Gastroenterol Nutr. 2011 Jul. 53(1):113-4. [Medline].

  30. Geer RJ, Richards WO, O'Dorisio TM, Woltering EO, Williams S, Rice D, et al. Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Ann Surg. 1990 Dec. 212(6):678-87. [Medline].

  31. Didden P, Penning C, Masclee AA. Octreotide therapy in dumping syndrome: Analysis of long-term results. Aliment Pharmacol Ther. 2006 Nov 1. 24(9):1367-75. [Medline].

  32. Moreira RO, Moreira RB, Machado NA, Gonçalves TB, Coutinho WF. Post-prandial hypoglycemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg. 2008 Dec. 18(12):1618-21. [Medline].

  33. Zhang J, Chen JD. Systematic review: applications and future of gastric electrical stimulation. Aliment Pharmacol Ther. 2006 Oct 1. 24(7):991-1002. [Medline].

  34. Wei HB, Wei B, Zheng ZH, et al. Comparative study on three types of alimentary reconstruction after total gastrectomy. J Gastrointest Surg. 2008 Aug. 12(8):1376-82. [Medline].

  35. Nunobe S, Sasako M, Saka M, et al. Symptom evaluation of long-term postoperative outcomes after pylorus-preserving gastrectomy for early gastric cancer. Gastric Cancer. 2007. 10(3):167-72. [Medline].

  36. Nakane Y, Michiura T, Sakuramoto K, et al. [Evaluation of the preserved function of the remnant stomach in pylorus preserving-gastrectomy by gastric emptying scintigraphy] [Japanese]. Gan To Kagaku Ryoho. 2007 Jan. 34(1):25-8. [Medline].

  37. Porter HW, Claman ZB. A preliminary report on the advantage of small stoma in partial gastrectomy for ulcer. Ann Surg. 1954. 129:417.

  38. Woodward ER, Desser PL, Gasster M. Surgical treatment of postgastrectomy dumping syndrome. West J Surg. 1955. 63:567.

  39. Koruth NM, Krukowski ZH, Matheson NA. Pyloric reconstruction. Br J Surg. 1985 Oct. 72(10):808-10. [Medline].

  40. Cheadle WG, Baker PR, Cuschieri A. Pyloric reconstruction for severe vasomotor dumping after vagotomy and pyloroplasty. Ann Surg. 1985 Nov. 202(5):568-72. [Medline].

  41. Henley FA. Experiences with jejunal interposition for correction of postgastrectomy syndromes. Harkins HN, Nyhus LM, eds. Surgery of the Stomach and Duodenum. Boston, Mass: Little Brown and Company; 1969. 777.

  42. Wong PY, Talamo RC, Babior BM, Raymond GG, Colman RW. Kallikrein-kinin system in postgastrectomy dumping syndrome. Ann Intern Med. 1974 May. 80(5):577-81. [Medline].

  43. Malik S, Mitchell JE, Steffen K, et al. Recognition and management of hyperinsulinemic hypoglycemia after bariatric surgery. Obes Res Clin Pract. 2016 Jan-Feb. 10 (1):1-14. [Medline].

  44. Sawyers JL, Herrington JL Jr. Superiority of antiperistaltic jejunal segments in management of severe dumping syndrome. Ann Surg. 1973 Sep. 178(3):311-21. [Medline].

  45. Vogel SB, Hocking MP, Woodward ER. Clinical and radionuclide evaluation of Roux-Y diversion for postgastrectomy dumping. Am J Surg. 1988 Jan. 155(1):57-62. [Medline].

  46. Hammer HF. Medical complications of bariatric surgery: focus on malabsorption and dumping syndrome. Dig Dis. 2012. 30(2):182-6. [Medline].

  47. Zurita Mv LC, Tabari M, Hong D. Laparoscopic conversion of laparoscopic Roux-en-Y gastric bypass to laparoscopic sleeve gastrectomy for intractable dumping syndrome and excessive weight loss. Surg Obes Relat Dis. 2012 Nov 30. [Medline].

  48. Dapri G, Cadière GB, Himpens J. Laparoscopic reconversion of Roux-en-Y gastric bypass to original anatomy: technique and preliminary outcomes. Obes Surg. 2011 Aug. 21(8):1289-95. [Medline].

  49. Parikh M, Pomp A, Gagner M. Laparoscopic conversion of failed gastric bypass to duodenal switch: technical considerations and preliminary outcomes. Surg Obes Relat Dis. 2007 Nov-Dec. 3(6):611-8. [Medline].

  50. Papamargaritis D, Koukoulis G, Sioka E, et al. Dumping symptoms and incidence of hypoglycaemia after provocation test at 6 and 12 months after laparoscopic sleeve gastrectomy. Obes Surg. 2012 Oct. 22(10):1600-6. [Medline].

  51. Meier JJ, Butler AE, Galasso R, Butler PC. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care. 2006 Jul. 29(7):1554-9. [Medline]. [Full Text].

  52. Kellogg TA, Bantle JP, Leslie DB, et al. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis. 2008 Jul-Aug. 4(4):492-9. [Medline].

  53. Abbott WE, Krieger H, Levey S. Technical surgical factors which enhance or minimize postgastrectomy abnormalities. Ann Surg. 1958. 148:567.

  54. Abell TL, Minocha A. Gastrointestinal complications of bariatric surgery: diagnosis and therapy. Am J Med Sci. 2006 Apr. 331(4):214-8. [Medline].

  55. Andreasen JJ, Orskov C, Holst JJ. Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy. Digestion. 1994. 55(4):221-8. [Medline].

  56. Blackburn AM, Christofides ND, Ghatei MA, Sarson DL, Ebeid FH, Ralphs DN, et al. Elevation of plasma neurotensin in the dumping syndrome. Clin Sci (Lond). 1980 Oct. 59(4):237-43. [Medline].

  57. Bloom SR, Royston CM, Thomson JP. Enteroglucagon release in the dumping syndrome. Lancet. 1972 Oct 14. 2(7781):789-91. [Medline].

  58. Burkhalter E. Incidence of gastrectomy in United States army hospitals worldwide from 1975 to 1985. Am J Gastroenterol. 1988 Nov. 83(11):1231-4. [Medline].

  59. Carvajal SH, Mulvihill SJ. Postgastrectomy syndromes: dumping and diarrhea. Gastroenterol Clin North Am. 1994 Jun. 23(2):261-79. [Medline].

  60. Cranley B, Kelly KA, Go VL, McNichols LA. Enhancing the anti-dumping effect of Roux gastrojejunostomy with intestinal pacing. Ann Surg. 1983 Oct. 198(4):516-24. [Medline].

  61. Duthie HL, Irvine WT, Kerr JW. Cardiovascular changes in post-gastrectomy syndrome. Br J Surg. 1959. 46:350.

  62. Eisenberg MM, Woodward ER, Carson TJ, Dragstedt LR. Vagotomy and drainage procedure for duodenal ulcer: the results of ten years' experience. Ann Surg. 1969 Sep. 170(3):317-28. [Medline].

  63. Gonzalez-Sanchez JA, Corujo-Vazquez O, Sahai-Hernandez M. Bariatric surgery patients: reasons to visit emergency department after surgery. Bol Asoc Med P R. 2007 Oct-Dec. 99(4):279-83. [Medline].

  64. Gray JL, Debas HT, Mulvihill SJ. Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. Arch Surg. 1991 Oct. 126(10):1231-5; discussion 1235-6. [Medline].

  65. Gustavsson S, Kelly KA, Melton LJ 3rd, Zinsmeister AR. Trends in peptic ulcer surgery. A population-based study in Rochester, Minnesota, 1956-1985. Gastroenterology. 1988 Mar. 94(3):688-94. [Medline].

  66. Hasler WL, Soudah HC, Owyang C. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther. 1996 Jun. 277(3):1359-65. [Medline].

  67. Hockings MP, Vogel SB. Woodward's postgastrectomy syndromes. Philadelphia, Pa: WB Saunders; 1991. 195.

  68. Hoffmann J, Jensen HE, Christiansen J, Olesen A, Loud FB, Hauch O. Prospective controlled vagotomy trial for duodenal ulcer. Results after 11-15 years. Ann Surg. 1989 Jan. 209(1):40-5. [Medline].

  69. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology. 1994 Dec. 107(6):1848-55. [Medline].

  70. Hopman WP, Wolberink RG, Lamers CB, Van Tongeren JH. Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Ann Surg. 1988 Feb. 207(2):155-9. [Medline].

  71. Johnson LP, Jesseph JE. Evidence of a humoral etiology of the dumping syndrome. Surg Forum. 1961. 12:316.

  72. Johnston D, Blackett RL. A new look at selective vagotomies. Am J Surg. 1988 Nov. 156(5):416-27. [Medline].

  73. Karamanolis G, Tack J. Nutrition and motility disorders. Best Pract Res Clin Gastroenterol. 2006. 20(3):485-505. [Medline].

  74. Khoshoo V, Reifen RM, Gold BD, Sherman PM, Pencharz PB. Nutritional manipulation in the management of dumping syndrome. Arch Dis Child. 1991 Dec. 66(12):1447-8. [Medline].

  75. Krieger H, Levey S. Technical surgical factors which enhance or minimize postgastrectomy abnormalities. Ann Surg. 1958. 148:567.

  76. Lamers CB, Bijlstra AM, Harris AG. Octreotide, a long-acting somatostatin analog, in the management of postoperative dumping syndrome. An update. Dig Dis Sci. 1993 Feb. 38(2):359-64. [Medline].

  77. Lawaetz O, Blackburn AM, Bloom SR, Aritas Y, Ralphs DN. Gut hormone profile and gastric emptying in the dumping syndrome. A hypothesis concerning the pathogenesis. Scand J Gastroenterol. 1983 Jan. 18(1):73-80. [Medline].

  78. Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci. 1995 May. 40(5):1074-82. [Medline].

  79. LeQuesne LP, Hobsley M, Hand BH. The dumping syndrome I. Factors responsible for the symptoms. Br Med J. 1960. 1:141.

  80. Lygidakis NJ. A new method for the surgical treatment of the dumping syndrome. Ann R Coll Surg Engl. 1981 Nov. 63(6):411-4. [Medline].

  81. Machella TE. The mechanism of postgastrectomy dumping. Surg. 1949. 130:145.

  82. Mackie CR, Jenkins SA, Hartley MN. Treatment of severe postvagotomy/postgastrectomy symptoms with the somatostatin analogue octreotide. Br J Surg. 1991 Nov. 78(11):1338-43. [Medline].

  83. Meyer JH, Thompson JB, Cohen MB. Motility of the stomach and the gastroduodenal junction. Johnson LR, ed. The Physiology of the Gastrointestinal Tract. 2nd ed. New York, NY: Raven Press; 1987. 625-9.

  84. Meyer JH, Thomson JB, Cohen MB, Shadchehr A, Mandiola SA. Sieving of solid food by the canine stomach and sieving after gastric surgery. Gastroenterology. 1979 Apr. 76(4):804-13. [Medline].

  85. Miholic J, Reilmann L, Meyer HJ, Körber H, Kotzerke J, Hecker H. Extracellular space, blood volume, and the early dumping syndrome after total gastrectomy. Gastroenterology. 1990 Oct. 99(4):923-9. [Medline].

  86. Mix CL. Dumping following gastrojejunostomy. Surg Clin North Am. 1922. 2:617.

  87. Norryd C, Dencker H, Lunderquist A, Olin T, Tylén U. Superior mesenteric blood flow during experimentally induced dumping in man. Acta Chir Scand. 1975. 141(3):187-96. [Medline].

  88. Overton RC, Jordon GLJ, DeBakey ME. The postgastrectomy syndrome: studies of pathogenesis. Ann Surg. 1957. 145:471.

  89. Paimela H, Tuompo PK, Perakyl T, Saario I, Hockerstedt K, Kivilaakso E. Peptic ulcer surgery during the H2-receptor antagonist era: a population-based epidemiological study of ulcer surgery in Helsinki from 1972 to 1987. Br J Surg. 1991 Jan. 78(1):28-31. [Medline].

  90. Pedersen JH, Beck H, Shokouh-Amiri M, Fischer A. Effect of neurotensin in the dumping syndrome. Scand J Gastroenterol. 1986 May. 21(4):478-82. [Medline].

  91. Perman E. The so-called dumping syndrome after gastrectomy. Acta Med Scan. 1947. 128 (suppl 196):361.

  92. Ralphs DN, Thomson JP, Haynes S, Lawson-Smith C, Hobsley M, Le Quesne LP. The relationship between the rate of gastric emptying and the dumping syndrome. Br J Surg. 1978 Sep. 65(9):637-41. [Medline].

  93. Roberts KE, Randall HT, Farr HW. Cardiovascular and blood volume alterations resulting from intrajejunal administration of hypertonic solutions to gastrectomized patients: The relationship of these changes to the dumping syndrome. Ann Surg. 1954. 140:631.

  94. Rubio MA, Moreno C. [Nutritional implications of bariatric surgery on the gastrointestinal tract] [Spanish]. Nutr Hosp. 2007 May. 22 Suppl 2:124-34. [Medline].

  95. Sagor GR, Bryant MG, Ghatei MA, Kirk RM, Bloom SR. Release of vasoactive intestinal peptide in the dumping syndrome. Br Med J (Clin Res Ed). 1981 Feb 14. 282(6263):507-10. [Medline].

  96. Sawyers JL. Management of postgastrectomy syndromes. Am J Surg. 1990 Jan. 159(1):8-14. [Medline].

  97. Sigstad H. A clinical diagnostic index in the diagnosis of the dumping syndrome. Changes in plasma volume and blood sugar after a test meal. Acta Med Scand. 1970 Dec. 188(6):479-86. [Medline].

  98. Smith L, Smithers M, Prins J, O'Moore-Sullivan T. Acute and long-term effect of alpha-glucosidase inhibitor on dumping syndrome in a patient after a vagotomy and pyloric surgery. ANZ J Surg. 2005 Dec. 75(12):1124-6. [Medline].

  99. Snook JA, Wells AD, Prytherch DR, Evans DH, Bloom SR, Colin-Jones DG. Studies on the pathogenesis of the early dumping syndrome induced by intraduodenal instillation of hypertonic glucose. Gut. 1989 Dec. 30(12):1716-20. [Medline].

  100. Tack J. Gastric motor disorders. Best Pract Res Clin Gastroenterol. 2007. 21(4):633-44. [Medline].

  101. Tulassay Z, Tulassay T, Gupta R, Cierny G. Long acting somatostatin analogue in dumping syndrome. Br J Surg. 1989 Dec. 76(12):1294-5. [Medline].

  102. van der Kleij FG, Vecht J, Lamers CB, Masclee AA. Diagnostic value of dumping provocation in patients after gastric surgery. Scand J Gastroenterol. 1996 Dec. 31(12):1162-6. [Medline].

  103. Vetch J, Lambers RJ. Octreotide influences small intestinal motility and transit time in fasting and fed states. Gastro. 1994. 106:A583.

  104. Visick AH. A study of the failures after gastrectomy. Ann R Coll Surg Engl. 1948. 3:266.

  105. Wick JY. Coming to a facility near you: the bariatric surgery patient. Consult Pharm. 2006 Nov. 21(11):874-76, 878-80, 882, 885-6. [Medline].

  106. Yamada M, Ohrui T, Asada M, et al. Acarbose attenuates hypoglycemia from dumping syndrome in an elderly man with gastrectomy. J Am Geriatr Soc. 2005 Feb. 53(2):358-9. [Medline].

  107. Zeitlin IJ, Smith AN. 5-hydroxyindoles and kinins in the carcinoid and dumping syndromes. Lancet. 1966 Nov 5. 2(7471):986-91. [Medline].

 
Previous
Next
 
Pathophysiology of dumping syndrome.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.